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Abstract
Background: High serum lactate is associated with increased mortality in septic shock patients. Metformin alters
lactate metabolism, and may affect its prognostic value. We compared, between metformin users and nonusers, the
prognosis of extremely elevated plasma lactate levels in patients with septic shock.
Methods: The electronic medical records (EMR) of patients admitted to the emergency room between January
2011 and June 2013 were reviewed. The study cohort comprised patients with an initial diagnosis of septic shock
and blood lactate higher than 10 mmol/L. The selected population was divided into two groups: metformin users
(exposed) and metformin nonusers (unexposed). The primary outcome measured was inhospital mortality.
Results: The study included 44 metformin users and 118 nonusers. Metformin users were similar to nonusers with
respect to levels of lactate, HCO3, and blood pH; however, they were older and had higher incidence rates of
cardiovascular disease and acute kidney injury at admission, compared to nonusers. Inhospital mortality rates were
significantly lower in the metformin-treated group, 56.8 % vs. 88.1 %, p <0.0001.
Conclusions: Though high lactate concentration indicates poor prognosis in septic patients, mortality rate was
found to be significantly lower in those who were treated with metformin. This finding may help clinicians in
deciding treatment for these patients, who could otherwise be considered too ill for real treatment benefit.
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Background
Lactic acidosis, defined as plasma lactate concentration
greater than 5 mM and blood pH lower than 7.35, is
common among emergency room (ER) and intensive
care unit (ICU) patients. Lactic acidosis generally results
from marked tissue hypoperfusion in shock or follows
cardiopulmonary arrest; and as such, serves as an indica-
tor of increased mortality risk [1, 2]. Elevated serum lac-
tate is associated with increased mortality, independent
of organ failure and shock [3–5]. Metformin, which is
currently considered the first choice for oral treatment
of type 2 diabetes [6], may interfere with lactate metab-
olism. However, the prognosis among metformin users,
compared to nonusers, of severe sepsis, with highly ele-
vated lactate, is unclear.
The causes of lactic acidosis can be divided into those
associated with obviously impaired tissue oxygenation
(type A) and those in which systemic impairment in
oxygenation does not exist or is not readily apparent
(type B). The accumulation of lactate is usually due to
enhanced pyruvate production; reduced pyruvate con-
version to carbon dioxide and water, or to glucose; and
an altered redox state within the cell, in which the pyru-
vate/lactate ratio shifts toward lactate. Lactic acidosis in-
duced by metformin is typical, but a rare form of type B
lactic acidosis, termed metformin-induced lactic acidosis
(MILA). When lactic acidosis is diagnosed in a patient
treated with metformin, but metformin overdose is not
detected, the term metformin-associated lactic acidosis
(MALA) better describes the condition. The exact cellu-
lar mechanism responsible for lactate accumulation
under metformin treatment was unclear for many years,
but a recent trial revealed that metformin selectively
inhibits the mitochondrial isoform of glycerophosphate
dehydrogenase, an enzyme that catalyzes the conversion
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of glycerophosphate to dihydroxyacetone phosphate
(DHAP). As a result, cytosolic DHAP is reduced and the
cytosolic NAD–NADH ratio is increased [7]. Cellular ac-
cumulation of NAD inhibits the conversion of lactate to
pyruvate (limits the use of lactate as gluconeogenic
precursors) and culminates in increased plasma concen-
tration of lactate [7]. Metformin also interacts in a dose-
dependent manner with hepatic and extrahepatic mito-
chondrial enzymes [8], and this inhibits global oxygen
consumption [9].
The incidence of lactic acidosis in metformin users
appears to be very low [10–13]. Nevertheless, MALA re-
mains a concern because of the high case-fatality rate,
about 50 %. Most cases of MALA occur in patients with
conditions that predispose to hypoperfusion and hypox-
emia, such as heart or respiratory failure, or hypotension
[10, 11, 14]. MILA occurs during acute overdose of met-
formin in the case of suicide attempts, and can induce
severe lactic acidosis. However, unlike type A lactic acid-
osis, where the underlying cause cannot be easily cor-
rected or removed, the prognosis in MILA is relatively
good, and patients with blood lactate as high as
40 mmol/L may survive [15].
The aim of the present study was to compare, between
metformin users and nonusers, the prognosis of ex-
tremely elevated plasma lactate levels and septic shock
at arrival to the ER.
Methods
The electronic medical records (EMR) of all patients
admitted to the ER of Assaf Harofeh Medical Center in
Israel between 1 January 2011 and 1 June 2013 were
reviewed. The study comprised a cohort of patients
diagnosed with septic shock and severe lactic acidosis.
The study protocol was approved by the Assaf Harofeh
Institutional Review Board (IRB).
Study inclusion criteria were age older than 18 years,
blood lactate higher than 10 mg/dL and an initial diag-
nosis of septic shock (ICD-9 codes 995.90–94) in the
patients’ files. Septic shock is diagnosed by the ER
physician when there is an objective (or assumed) in-
fectious origin/site, together with hemodynamic in-
stability, inflammatory markers and organ dysfunction.
Patients with seizures, acute bleeding, acute surgical
conditions or trauma were excluded from the study.
The selected population was divided into two groups:
metformin users (exposed) comprised patients who
were actively treated with metformin for at least
3 months just prior to their admission; and metformin
nonusers (unexposed) comprised patients who did not
meet this criterion.
The clinical standard in the ER is that blood chemistry
and blood gases are analyzed for each patient with signs
of shock. If high anion gap metabolic acidosis is
detected, lactate level is measured. Thus, the EMR data
regarding patient analysis on admission could be effect-
ively screened. In addition, patients’ baseline characteris-
tics, including their medical history, presence of
diabetes, and blood creatinine levels were recorded.
Acute kidney injury (AKI) was determined using risk,
injury, failure, loss, end stage (RIFLE) criteria, defined as
a twofold increase in serum creatinine, or an estimated
glomerular filtration rate (eGFR) (according to the
Modification of Diet in Renal Disease (MDRD) study
equation) decrease by 50 percent compared to baseline
[16]. Preadmission creatinine value was defined as the
last value obtained from the hospital’s database or from
the managed care organization (outpatient) database.
Baseline values were used if they were obtained within
the year prior to the relevant admission.
Patient medications were accessed from recordings by
ER physicians, based on medical records or anamnesis
taken from patients or from those accompanying them.
Serum lactate (mmol/L) level was measured using a
serum-based immunoassay (Unicel Synchron, Beckman
Coulter Inc., Brea, CA, USA) and blood gases were ana-
lyzed in the ER using Cobas b 221 (Roche Diagnostics,
Basel, Switzerland). Acute physiology and chronic health
evaluation (APACHE) II score was calculated for all pa-
tients admitted to the ICU, using their values at the first
24 hours.
The primary outcome measure was inhospital mortal-
ity. Patients were followed until hospital discharge. Time
to event was defined as the time from hospitalization to
discharge or death.
Statistical analysis
Data are expressed as mean ± standard deviation (SD),
or median and interquartile range (Q1 to Q3), for vari-
ables that did not follow a normal distribution, and as
percentages for categorical variables. Normally distrib-
uted continuous variables were compared between the
metformin user and nonuser groups by means of a two-
sided t test and with chi-square tests for categorical vari-
ables. Since the APACHE II score, creatinine level at
admission, and preadmission creatinine levels were not
normally distributed, median scores were used for com-
parisons using the nonparametric Mann–Whitney U
test. Univariate and multivariate Cox regression analyses
are presented as Cox analysis hazard ratios (HR) with
confidence intervals (CI). The selection of variables for
multivariate models was based on a univariate analysis
of each variable. Any variable having a significant univar-
iate test at some arbitrary level was selected as a candi-
date for the multivariate analysis. We based this on the
p value cutoff point of 0.25. Survival analyses were per-
formed using the Kaplan–Meier survival curve and the
Cox proportional hazard model.
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All statistical tests were two-sided, with a value for
p <0.05 defining significance.
All statistical analyses were performed using SPSS soft-
ware, version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Of 395,783 patients admitted to the ER during the study
period, 195 were with septic shock and severe lactic
acidosis (blood lactate level >10 mmol/L) (Fig. 1).
Thirty-three patients were excluded from analysis due to
uncertainty regarding their chronic medication use.
Forty-four of the recruited patients were chronically
treated with metformin. The 118 patients who were not
treated with metformin served as the unexposed group.
Baseline patient characteristics are summarized in
Table 1. There were no statistically significant differences
between the groups regarding levels of lactate or HCO3,
or blood pH at admission. However, compared to the
control group, metformin users were older 74.0 ± 11.3 vs.
68.4 ± 19.7 years (p = 0.03), and had higher cardiovas-
cular risk due to higher incidence of diabetes mellitus,
ischemic heart disease and cerebrovascular attacks. Mean
preadmission creatinine levels were similar, 1.2 mg/dL vs.
1.1 mg/dL for metformin users and nonusers, respectively,
(p = 0.36). However, metformin users had higher mean
creatinine levels at admission (2.87 vs. 2.14, p = 0.02),
and higher incidence of AKI (Table 1). Both groups
had very high APACHE II score (and thus expected
mortality); however, the mean APACHE II score
among metformin users was higher, 41.12 ± 8.8 vs.
37.97 ± 6.16, p = 0.01. The mean metformin dose was
1.6 ± 0.8 g per day. Suspected origins of infection
were confirmed for most of the 44 metformin users:
22 (50 %) had bacteremia, 5 (12 %) had bacteriuria, 3
(7 %) had pneumonia on chest X-ray and 5 (11 %)
had skin or wound infection.
The inhospital mortality rate was significantly lower in
the metformin-treated group, 56.8 % compared to
88.1 %, despite the more severe risk factors in the
former. The Cox analysis HR for inhospital mortality for
the metformin group was 0.439, p <0.0001.
In a risk factor analysis, age, diabetes and metformin use
were significantly associated with the risk for inhospital
395,783
Patients were admitted to
the ER between
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Fig. 1 Patient flow






Gender (male), n (%) 22 (50 %) 71 (60.17 %) 0.09
Age (mean ± SD) 74.0 ± 11.3 68.4 ± 19.7 0.03
Baseline creatinine 1.2 (0.7–1.3) 1.1 (0.7–1.2) 0.36
Hypertension, n (%) 34 (77.3) 26 (52.5) <0.001
ACEi, n (%) 18 (40.9) 26 (22.0) 0.29
Beta blockers, n (%) 27 (61.4) 37 (31.4) 0.09
Diabetes, n (%) 44 (100) 23 (19.83) <0.001
Metformin dose (g) 1.6 (0.8)
Insulin n (%) 9 (20.5) 13 (11.4) <0.001
Ischemic heart disease, n (%) 15 (34.1) 358 (29.7) 0.05
Cerebrovascular attack, n (%) 14 (32.6) 23 (19.5) 0.02
Aspirin use, n (%) 20 (45.5) 318 (26.3) 0.65
Malignancy, n (%) 8 (18.2) 21 (17.8) <0.001
Lactate (median, IQR) 12.7 (11.1–15.0) 12.7 (11.3–16.3) 0.90
Ph (median, IQR) 7.06 (6.9–7.20) 7.10 (6.94–7.20) 0.80
HCO3 (mean ± SD) 10.9 ± 5.6 11.5 ± 5.1 0.56
APACHE II score 41.12 ± 8.8 37.97 ± 6.16 0.01
Mortality score 34.7(11.7–55.6) 43.9 (31.5–59.6) 0.19
Creatinine at admission 2.87 (1.5–3.32) 2.14 (1.21–3) 0.02
Acute kidney injury (%) 38 (86.7 %) 65 (56.7 %) 0.02
Renal replacement therapy (%) (38.6 %) 17 25 (21.2 %) 0.13
Inhospital mortality 25 (556.8 %) 104 (88.1 %) <0.001
Time to event (hospitalization
to death or discharge, days,
mean ± SD)
11.67 ± 15.3 4.77 ± 9.79 <0.001
Data presented as mean ± standard deviation (SD) or median and
interquartile (IQR) range for parameters not normally distributed or as %
for categorical variables
ACEi angiotensin-converting enzyme inhibitor, APACHE II acute physiology and
chronic health evaluation II
*p for t test or for Mann–Whitney test for parameters not normally distributed
or chi2 for categorical
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mortality, with HRs of 1.05 (1.01–1.08), p = 0.05; 0.5
(0.34–0.74); p = 0.01; and 0.42 (0.27–0.66), respectively
(Table 2). For the high range of lactate levels of the
present cohort (all greater than 10 mmol/L), lactate
level had no prognostic value for the entire cohort,
or for metformin users or for nonusers separately
(HR = 1.06 (0.99–1.1), p = 0.284, HR = 1.04 (0.96–1.16),
p = 0.129 and HR = 1.05 (0.99–1.11), p = 0.091, re-
spectively (Table 2).
In a multivariate analysis, that adjusted for age, gender,
diabetes, hypertension, ischemic heart disease, cerebro-
vascular disease, malignancy, levels of creatinine and lac-
tate at admission, and APACHE II score, the HR for
inhospital mortality among metformin users was 0.207
(CI 0.046–0.939), p = 0.041. Kaplan–Meier curves showed
greater cumulative survival for the metformin group dur-
ing hospitalization (Fig. 2).
Survivors and nonsurvivors among metformin users
were further compared. Among metformin users, survi-
vors showed higher incidence of acute renal failure and
a greater frequency of hemodialysis, yet lower APACHE
scores, than did nonsurvivors (Table 3).
Discussion
In a cohort of patients admitted to the ER with severe
lactic acidosis and sepsis, the rate of inhospital mortality
was lower for those who were actively treated with
metformin than for those who were not, 56.8 % vs.
88.1 %, p <0.0001. The unexpected relatively high sur-
vival rate of metformin users distinguishes them as pa-
tients who may benefit from intensive treatment.
Lactate was first suggested as a clinical prognostic tool
by Broder and Weil in 1964 when they observed that a
level of >4 mmol/L was associated with poor outcomes
in patients with undifferentiated shock [17, 18]. Since
then, much has been published on the etiology and
treatment of elevated lactate levels in a variety of patient
populations [17, 18]. The role of blood lactate as a
marker of tissue hypoperfusion has demonstrated prog-
nostic value [3, 4, 19]. Moreover, hyperlactatemia has
been suggested as an obligatory diagnostic criterion for
septic shock [19]. The current study examined patients
with septic shock and extremely severe lactic acidosis,
represented by blood lactate higher than 10 mmol/L at
hospital admission. The very high mortality rate ob-
served further supports the prognostic value of high
lactate levels in risk assessment of septic patients. How-
ever, the prognostic value of lactic acidosis in metformin
users was different, as reflected by better survival. Their
lower mortality rate is particularly remarkable in light of
the higher risk profile of the metformin users: older
mean age, higher incidence rates of diabetes, cardiovas-
cular diseases and AKI.
Septic shock is clearly a condition of hypoperfusion
and hypoxemia that predisposes to lactate generation.
However, sepsis may also alter metformin metabolism.
Metformin is eliminated rapidly and actively by the kid-
ney and any decrease in renal perfusion and/or acute
tubular injury, as happens during AKI, may lead to met-
formin accumulation [20]. Though metformin users in
the current study were treated with standard doses, not
exceeding 2550 mg/day, 86.7 % of them had AKI, which
may predispose to metformin accumulation. While the
prognostic value of sepsis-induced lactic acidosis is se-
vere, the prognosis of pure metformin intoxication is
significantly better (patients with blood lactate as high as
40 mg/dL may survive).
In addition to metformin accumulation and amplifica-
tion of hypoxic-induced lactate generation, metformin
has pleiotropic effects that may be beneficial during crit-
ical illness. Preclinical and clinical studies showed that
metformin has anti-inflammatory [21, 22] and anti-
thrombotic [23] effects. Metformin induces activation
of AMP-activated protein kinase (AMPK) [19, 20], an
enzyme that is normally induced by cellular stress
and hypoxia/anoxia [23, 24]. Once activated, AMPK
regulates cellular energy status; it switches on the
Table 2 Hazard ratios and confidence intervals for inhospital
mortality




N = 162 n = 44 n = 118
Age (1 year↑) 1.05 (1.02–1.08)P 0.99 (0.95–1.02) 1.05P (1.0–1.08)
Gender (male) 0.83 (0.58–1.18) 0.67 (0.30–1.14) 0.88 (0.59–1.32)
Diabetes 0.50 (0.34–0.74)P — 0.82 (0.48–1.40)
Hypertension 0.79 (0.55–1.14) 0.47 (0.19–1.14) 1.12 (0.74–1.65)
IHD 1.22 (0.83–1.78) 0.88 (0.37–2.06) 1.55P (1.01–2.4)
Cerebrovascular attack 1.09 (0.72–1.65) 1.57 (0.69–3.50) 1.15 (1.01–2.40)
Lactate (1 mg/dL↑) 1.06 (0.99–1.10) 1.04 (0.96–1.16) 1.05 (0.99–1.11)
pH 0.91 (0.37–2.26) 1.02 (0.16–6.45) 1.05 (0.99–1.11)
Bicarbonate (1 meq/L↑) 0.97 (0.93–1.01) 0.99 (0.92–1.06) 0.97 (0.93–1.01)
APACHE II (1↑) 1.03 (0.99–1.07) 1.10 (1.01–1.20)P 0.99 (0.95–1.04)
Acute kidney injury 0.93 (0.62–1.40) 0.80 (2.37–2.68) 0.91 (0.54–1.50)
Creatinine (1 mg/dL↑) 0.92 (0.82–1.00) 0.91 (0.75–1.11) 1.08 (0.92–1.29)
Anion gap (1↑) 0.99 (0.97–1.01) 0.98 (0.94–1.02) 1.01 (0.98–1.04)
HD 0.61 (0.40–0.95)P 0.46 (0.19–1.11) 0.91 (0.54–1.50)
Temperature (1 °C) 0.94 (0.63–1.40) 0.89 (0.55–1.34) 0.98 (0.67–1.45)
Metformin 0.42 (0.27–0.66)P — —
Metformin adj* 0.21 (0.05–0.94)P — —
Univariate analyses are presented for the investigated variables. A multivariate
analysis is presented for metformin use
IHD ischemic heart disease, HD underwent hemodialysis, APACHE II acute
physiology and chronic health evaluation II.
PRefers to p <0.05
*Adjusted for age, gender, diabetes, hypertension, ischemic heart disease,
cerebrovascular disease, malignancy, levels of creatinine and lactate at
admission, and APACHE II score
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ATP-generating pathways and switches off the ATP-
consuming pathways [7]. This switch improves cellu-
lar function under stress conditions, such as improved
cardiovascular function during stress [25, 26].
The beneficial effect versus risk of metformin adminis-
tration in patients suffering from chronic kidney disease
(CKD) is a debatable issue. In the current study, popula-
tion preadmission creatinine levels of patients under
metformin treatment were within FDA guidelines (27),
which state that creatinine levels higher than 1.5 mg/dL
in males and 1.4 mg/dL in females, is a contraindication
to the use of metformin. Preadmission creatinine was
not a risk factor for lactate accumulation; it was acute
rather than chronic renal failure that was associated with
lactic acidosis. However, patients with CKD are at high
risk for AKI leading to metformin accumulation and
lactate generation. Considering the beneficial effects of
metformin for type II diabetes, the findings of this study
may support metformin administration to patients with
mild and stable CKD, but the risk of AKI should always
be considered.
The current study has several limitations. For one, lack
of measurement of circulating metformin levels pre-
cludes verifying an association between severe lactic
acidosis and metformin accumulation. An additional
limitation relates to the higher risk for lactic acidosis in
metformin users than in nonusers. While this could be
expected to result in selection bias, as metformin users
may be more likely to have lactate measurements, the
higher mean APACHE score in the metformin group
does not support such possibility.
Lastly, to achieve a “clear-cut” very high-risk popula-
tion, only patients with extremely elevated blood lactate
(>10 mmol/L) were included in the study. The upshot is
that conclusions for the effect of metformin in mild lac-
tic acidosis cannot be drawn.
Conclusions
Though high lactate concentration in septic shock pa-
tients indicates poor prognosis, prognosis was found to
be less severe among metformin users. This finding may
help clinicians in deciding treatment for these patients,
Fig. 2 Kaplan–Meier survival curve
Table 3 A comparison, among metformin users, of clinical
characteristics between survivors and nonsurvivors
Variable Survivors Nonsurvivors
N = 19 n = 25 p
pH (mean ± SD) 7.06 ± 0.29 7.05 ± 0.16 0.93
Bicarbonate (mEq/L) (mean ± SD) 11.6 ± 6.4 10.4 ± 5.2 0.52
APACHE II (mean ± SD) 16.0 ± 6.1 28.8 ± 8.2 0.006
Morscore* (median, range) 22.0 (9.7–34.5) 59.6 (37.7–78.9) 0.01
Creatinine* (md/dL) (median, range) 1.65 (1.29–5.08) 1.95 (1.50–2.88) 0.73
Pread cre* (mg/dL) (median, range) 0.85 (0.66–1.70) 0.87 (0.70–1.15) 0.83
Anion gap (mean ± SD) 30.4 ± 10.0 28.1 ± 8.6 0.46
HD** (%) 52.6 28.0 0.028
Body temperature (°C) (mean ± SD) 36.2 ± 1.5 36.0 ± 1.0 0.67
Data are represented as means ± standard deviations (SD), medians and
ranges, or percentages
APACHE II acute physiology and chronic health evaluation II, Morscore mortality
score, based on APACHE II score, Pread cre preadmission creatinine,
HD hemodialysis
p for t test, *Mann–Whitney or **chi-square
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who could otherwise be considered too ill for real treat-
ment benefit.
Key messages
 High lactate concentration in septic shock patients
treated with metformin appears to differ from that
presenting in patients who do not use metformin.
 The prognosis of metformin users suffering from
septic shock with severe lactic acidosis is significantly
better than that of patients who are not metformin
users.
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